1. Introduction
Sulphonamides are one of the essential pharmaceutical compound classes [
1,
2,
3,
4]. Over 5000 derivatives have been investigated for pharmaceutical applications, and 70 are used today. One example is sulfamidochrysoidine (trade name Prontosil), the first sulphonamide with pharmaceutical use and one of the first synthetic antibacterial drugs. It was discovered in 1932, reported in 1935, and honored with the Nobel Prize in medicine in 1939 [
5,
6]. Since then, sulphonamide drugs have been used in a wide range of applications, among others in antibacterial drugs [
7,
8,
9,
10], anti-diabetic agents [
11,
12,
13,
14,
15], antiretroviral drugs [
16,
17,
18,
19], nonsteroidal anti-inflammatory drugs [
20,
21,
22], and cardiac medications [
23,
24,
25].
Like many other modern pharmaceuticals, some sulphonamides lack bioavailability [
26,
27]. One well-documented way to overcome this problem and simultaneously improve other macroscopic properties is co-crystallisation [
28,
29,
30,
31]. By profoundly investigating interaction patterns, general patterns of sulphonamides might be found. This is based on the well-known synthon theory, which despite its failures is still the starting point of rational design and could lead not only to one co-crystal but to a whole new class of pharmaceutical-relevant co-crystals.
Halogen bonds (XBs), an attractive interaction of a halogen moiety’s (-Cl, -Br, -I) partially positive charged σ-hole with a partially negative charged area, is along with hydrogen bonding one of the most important anisotropic intermolecular interactions [
32]. There are numerous XBs; for example, strong XBs are formed with ions and oxygen and nitrogen moieties. XBs formed between two halogens are categorised into Type I and II based on the geometrical parameters [
33]. In some cases, the so-called Quasi Type I/II can occur [
34]. Some rare examples of XBs with aromatic π-systems have been reported [
35,
36,
37,
38]. These X···π interactions are weaker than the others mentioned because of the relatively widespread electron density along the π-system.
This work presents a series of rationally designed co-crystalline systems of selected sulphonamides with halogen-bonding donors (
Scheme 1). Selected survey objects range from the simplest archetypal sulphonamides to their pharmaceutically active derivative CPA. The simplest sulphonamides are N-methylbenzenesulphonamide (NMBSA) [
39], N-phenylmethanesulphonamide (NPMSA) [
40,
41], and N-phenylbenzenesulphonamide (BSA) [
42]. They are derivates only substituted by methyl and phenyl moieties, which are nonpolar and sterically manageable. On the other hand, there is Chlorpropamide (CPA) [
12], which has been used as an anti-diabetic agent. CPA is more complex and belongs to the sulphonamide subcategory sulphonylureas, which inhibit a urea-like moiety and are used to treat diabetes. It has six polymorphic modifications [
43,
44] and one known co-crystal with 4,4′-dipyridyl [
45]. The coformers, 1,4-diiodotetrafluorobenzene (14DITFB), 1,4-dibromotetrafluorobenzene (14DBTFB), and 1,2-diiodotetrafluorobenzene (12DITFB), are model XB coformers used in various studies to obtain multicomponent systems. Based on the obtained crystal structures, a topological analysis of intermolecular interactions with a primary emphasis on different types of halogen bonding is carried out.
3. Discussion
To give a broader context for the described XB patterns, in-depth research on intermolecular XB interactions of the three diiodotetrafluorobenzenes 12DITFB, 13DITFB, and 14DITFB in the Cambridge Structural Database (CSD) [
46] has been performed. Therefore, we analysed 553 structures and categorised the halogen bonds into four major groups, which are discussed in the following section. The results are presented in
Figure 8; all search parameters are listed in the
Supplementary Materials.
In the blue area, a total of 807 halogen bonds are depicted (583 I···N, 224 I···O). This group is the by far most populated one, which is hardly discernible since most of the points are overlapping. These interactions are the classic strong XBs, which are well-known and obviously often described [
32]. Therefore, these interactions are the ones we expected for our systems.
The area of XB interactions with aromatic systems is more extensive and diverse. Therefore, to increase the comparability, only C6 aromatic systems were considered. The distance (d), as well as the angle (∢), is measured relative to the centre of gravity (cg) for the same reason. The broadest category includes solely the I···cg interactions, without any XBs with a nitrogen or an oxygen (I···cg_w/o) atom being involved. The 101 I···cg interactions reach from 3.4 Å to 4.5 Å and from 50° to 180°. A cut-off was made at 4.5 Å since interactions at this point are almost impossible. The subgroup I···cg_opp within this category contains 23 XB interactions of DITFBs, which on the opposing iodine are interacting with nitrogen or oxygen. We had the hypothesis that they might behave with less direction and be more focused on the I···O/N site; hence, the stronger interaction with the electron-rich moieties should dominate the interaction pattern. But, interestingly, based on the scatterplot, no difference is noticeable compared to the I···cg_w/o, and the interactions are distributed in the whole green area. In contrast to that, I···cg_con indicates interactions where the same iodine entity shares both I···O/N and I···cg. From the 70 XB interactions found in the database, 62 are mostly caused by symmetry between “con” and “opp”. However, this subgroup, as indicated by the black line, is almost solely found in the region with longer distances and a lower angle. This is understandable considering the competing strong XB acceptor. Overall, the ratio between I···O/N and I···cg given in the literature is 4:1 (807:194). On the other hand, a more rigorous view on I···cg would move the ratio even further in favour of I···O/N.
The nine XBs in the presented structures
1–
7 are plotted as red stars in the scatterplot above and summarised in
Table 1 together with the van der Waals radii (vdW) [
47] for respective interactions. Three of these XBs are I···O/N and fit very well into analogue literature interactions (blue area). The remaining six interactions are I···cg_w/o or I···cg_opp interactions (green area). They are within the expected area, but all of them have a relatively high angle, and the XBs from
2–
6 also have a relatively short interaction distance.
Within this study, the co-crystallisation experiments with the basic sulphonamides were performed first, resulting in structures 1–4. These structures share I···O/N and I···cg equally, slightly overrepresenting the latter compared to the literature. Co-crystallisation experiments on a real-world example, namely CPA, followed to elucidate if the same result will occur for a more complex sulphonamide system. Interestingly, a strong I···O/N interaction was not formed in either of the resulting structures, 5–7. At this point, we began an in-depth analysis of the structures to clarify why the lessons learned from the small-model molecules are not transferable to the larger one and if there is a reason why I···cg might be stronger than I···O/N.
Newly synthesised compounds
2 and
3 both consist of the same entities of NPMSA and 14DITFB in different ratios, a phenomenon, which does not occur often for co-crystals. In some sense, it can be seen as a polymorphic behaviour. Similar to known examples of disappearing polymorphs [
48,
49], it was impossible to reproduce
3 in any possible way, which shows that it is disfavoured. Both structures have an intermolecular interaction with the sulphone oxygen moiety, but while in
3 both iodines of the 14DITFB are symmetry-equivalent, in
2 the second iodine interacts with a π-system. This comes from the significantly stronger I···O. It is likely that in the process of lattice formation, after forming this bond, it is sterically hindered since it needs to be elongated and rotated relative to the sulphone moiety. Therefore, the next-best option is forming an XB with the π-system favoured, leading to structure
2.
In contrast, co-crystal structures of CPA (
5–
7) show only XBs of the I···cg; CPA forming zig-zag-planes which are intercalated with the halogen bond donors naturally occurs for these structures. The backbone of these planes are strong hydrogen bond chains of the urea moiety, which are well known in the literature [
50,
51,
52]. However, the intermediate spaces seem to be somewhat larger than ideal for the halo-benzenes. For structures
5 and
6 it results in a longer I···cg bond than necessary, since the 14DITFB and 14DBTFB are secured by symmetry. For
7 the situation is slightly different. The iodines are not in a para but in an ortho position, and the aromatic centres are in a far-from-ideal position, resulting in the longest XB (d(I1···cg) = 4.168 Å).
Let us go back to the initial thought that XBs in sulphonamide systems might prefer π-systems over O/N-moieties as acceptors. More realistically, the HBs are stronger and, therefore, the predominant building blocks are either catameric structures (
1,
4–
7) or dimeric structures (
2,
3). The halogens take what was left, following Ostwald’s rule of stages [
53]. So XBs with π-systems have become a common interaction within the investigated structures against our expectations based on statistical knowledge and model sulphonamide co-crystal structures.
4. Materials and Methods
4.1. Synthesis of NMBSA-14DITFB (1:1), 1
Single crystals of 1 suitable for SCXRD were synthesised by dissolving NMBSA (10 mg, 58 µmol) and 14DITFB (12 mg, 30 µmol) in 1 mL of chloroform. The solution evaporated slowly at room temperature to give clear, colourless, plate-shaped crystals. The pure phase was obtained by neat-grinding NMBSA (45 mg, 261 µmol) and 1,4DITFB (105 mg, 263 µmol) in an MM 400 ball mill from Retsch with 20 Hz for 20 min.
4.2. Synthesis of NPMSA-14DITFB (1:1), 2
Single crystals of 2 suitable for SCXRD were obtained by dissolving NPMSA (10 mg, 58 µmol) and 14DITFB (12 mg, 30 µmol) in 1 mL of acetonitrile. The solution rapidly evaporated at room temperature to give clear, colourless, plate-shaped crystals. The pure phase was then obtained by neat-grinding NMBSA (40 mg, 234 µmol) and 14DITFB (94 mg, 234 µmol) in an MM 400 ball mill from Retsch with 20 Hz for 30 min.
4.3. Synthesis of NPMSA-14DITFB (2:1), 3
Pure-phase and single crystals of 3 suitable for SCXRD were synthesised by dissolving NPMSA (10 mg, 58 µmol) and 14DITFB (12 mg, 30 µmol) in 1 mL of acetonitrile. Clear, colourless block-shaped crystals were obtained after several days via slow evaporation at room temperature. Phase 3 could not be reproduced under the same or several different conditions. All attempts led to either 2 or a mixture of the base components.
4.4. Synthesis of BSA-14DITFB (2:1), 4
Single crystals of 4 suitable for SCXRD were synthesised by dissolving BSA (10 mg, 42 µmol) and 14DITFB (9 mg, 22 µmol) in 1 mL of ethanol. The solution evaporated slowly at room temperature for several days to form clear, colourless block-shaped crystals. The pure phase was additionally obtained by neat-grinding BSA (80 mg, 343 µmol) and 14DITFB (69 mg, 172 µmol) in an MM 400 ball mill from Retsch with 20 Hz for 20 min.
4.5. Synthesis of CPA-14DITFB (2:1), 5
Clear, colourless block-shaped single crystals of 5 suitable for SCXRD were synthesised by dissolving CPA (45 mg, 163 µmol) and 14DITFB (65 mg, 163 µmol) in 1 mL of methanol. The solution rapidly evaporated at room temperature. The pure phase was obtained via liquid-assisted grinding CPA (270 mg, 976 µmol) with 14DITFB (196 mg, 488 µmol) and 20 µL of methanol in an MM 400 ball mill from Retsch with 20 Hz for 20 min.
4.6. Synthesis of CPA-14DBTFB (2:1), 6
Single crystals of 6 suitable for SCXRD were synthesised by dissolving CPA (39 mg, 1000 µmol) and 14DBTFB (70 mg, 1672 µmol) in 1 mL of methanol, followed by rapid evaporation at room temperature. Clear, colourless block-shaped crystals were formed overnight. The pure phase was obtained via liquid-assisted grinding CPA (260 mg, 940 µmol), 14DBTFB (145 mg, 470 µmol), and 20 µL methanol in an MM 400 ball mill from Retsch with 20 Hz for 20 min.
4.7. Synthesis of CPA-12DITFB (2:1), 7
Single crystals of 7 suitable for SCXRD were synthesised by fast solution evaporation of CPA (45 mg, 163 µmol) and 12DITFB (65 mg, 163 µmol) dissolved in 1 mL of methanol at room temperature. Clear, colourless block-shaped crystals were formed overnight. The pure phase was obtained by liquid-assisted grinding CPA (500 mg, 1806 µmol), 1,2DITFB (363 mg, 1806 µmol), and 20 µL methanol in an MM 400 ball mill from Retsch with 20 Hz for 20 min.
4.8. SCXRD
Single Crystal X-ray Diffraction of
1–
7: Suitable single crystals were selected and mounted with silicon oil on a cryo-loop. Diffraction data were recorded with a Rigaku XtaLAB Synergy S diffractometer with a Hybrid Pixel Array Detector. Diffraction data were recorded with ω-scans using a micro-focus sealed X-ray tube PhotonJet X-ray Source (Cu (λ= 1.54184 Å) or Mo (λ = 0.71073 Å)), mirror monochromator. Cell refinement, data reduction, and absorption correction were executed with CrysAlisPro [
54]. OLEX2 [
55] was used to solve the crystal structures with SHELXS and refine it with SHELXL [
56]. All non-hydrogen positions were refined with anisotropic displacement parameters. Hydrogens were positioned geometrically with U
iso(H
CH(aliph.)) = 1.5 U
eq and U
iso(H
CH(arom.)) = 1.2 U
eq, except for amide hydrogens, which were positioned and refined freely. The crystallographic data for structures
1–
7 have been deposited at the Cambridge Crystallographic Data Centre (CCDC 2258821-2258827). Important crystallographic data and refinement parameters for systems
1–
7 are listed in
Appendix A,
Table A1,
Table A2,
Table A3,
Table A4,
Table A5,
Table A6 and
Table A7. Figures were prepared with Mercury software (2022.3.0) [
57].
4.9. PXRD
Powder X-ray Diffraction measurements were performed on a Rigaku Miniflex diffractometer in θ/2θ geometry from 5° to 50° at ambient temperature using Cu Kα radiation (λ = 1.54182 Å) and a rotating sample holder. Simulations were carried out with Mercury software [
57]. All recorded PXRDs, including their comparison with the simulated ones, are available in the
Supplementary Materials.